# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-24-031005
Filing Date
2024-02-12
Accepted
2024-02-12 07:01:22
Documents
157
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | d600678d10k.htm iXBRL | 10-K | 4076771
2 | EX-10.23 | d600678dex1023.htm | EX-10.23 | 83314
3 | EX-10.24 | d600678dex1024.htm | EX-10.24 | 5017
4 | EX-21 | d600678dex21.htm | EX-21 | 7559
5 | EX-23 | d600678dex23.htm | EX-23 | 2779
6 | EX-31.1 | d600678dex311.htm | EX-31.1 | 10362
7 | EX-31.2 | d600678dex312.htm | EX-31.2 | 10331
8 | EX-32 | d600678dex32.htm | EX-32 | 4353
9 | EX-97 | d600678dex97.htm | EX-97 | 26083
15 | GRAPHIC | g600678g0129214653895.jpg | GRAPHIC | 3243
16 | GRAPHIC | g600678g0129214903245.jpg | GRAPHIC | 2511
17 | GRAPHIC | g600678g29l02.jpg | GRAPHIC | 73056
| Complete submission text file | 0001193125-24-031005.txt |  | 21438421

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
10 | XBRL TAXONOMY EXTENSION SCHEMA | teva-20231231.xsd | EX-101.SCH | 154147
11 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | teva-20231231_cal.xml | EX-101.CAL | 87633
12 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE | teva-20231231_def.xml | EX-101.DEF | 930203
13 | XBRL TAXONOMY EXTENSION LABEL LINKBASE | teva-20231231_lab.xml | EX-101.LAB | 991068
14 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | teva-20231231_pre.xml | EX-101.PRE | 998754
159 | EXTRACTED XBRL INSTANCE DOCUMENT | d600678d10k_htm.xml | XML | 4654993

Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-16174 | Film No.: 24617334
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)